Amani Makkouk
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Amani Makkouk has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Aliasger Karimjee Salem
University of Iowa
1 shared publication Anthony Lucas
Adicet Therapeutics, Menlo Park, California, USA
1 shared publicationArun Bhat
Adicet Therapeutics, Menlo Park, California, USA
1 shared publicationBlake T Aftab
Adicet Therapeutics, Menlo Park, California, USA
1 shared publication- Brett Gross
Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, Massachusetts
1 shared publication Cariad Chester
Stanford University
1 shared publication
Latest Publications
- Open Access
- 16 December 2021
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 9 (12) , e003441
Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma
Background Glypican-3 (GPC-3) is an oncofetal protein that is highly expressed in various solid tumors, but rarely expressed in healthy adult tissues and represents a rational target of particular relevance in hepatocellular carcinoma (HCC). Autologous chimeric antigen receptor (CAR) αβ T cell therapies have established significant clinical benefit in hematologic malignancies, although efficacy in solid tumors has been limited due to several challenges including T cell homing, target antigen heterogeneity, and immunosuppressive tumor microenvironments. Gamma delta (γδ) T cells are highly cytolytic effectors that can recognize and kill tumor cells through major histocompatibility complex (MHC)-independent antigens upregulated under stress. The Vδ1 subset is preferentially localized in peripheral tissue and engineering with CARs to further enhance intrinsic antitumor activity represents an attractive approach to overcome challenges for conventional T cell therapies in solid tumors. Allogeneic Vδ1 CAR T cell therapy may also overcome other hurdles faced by allogeneic αβ T cell therapy, including graft-versus-host disease (GvHD). Methods We developed the first example of allogeneic CAR Vδ1 T cells that have been expanded from peripheral blood mononuclear cells (PBMCs) and genetically modified to express a 4-1BB/CD3z CAR against GPC-3. The CAR construct (GPC-3.CAR/secreted interleukin-15 (sIL)-15) additionally encodes a constitutively-secreted form of IL-15, which we hypothesized could sustain proliferation and antitumor activity of intratumoral Vδ1 T cells expressing GPC-3.CAR. Results GPC-3.CAR/sIL-15 Vδ1 T cells expanded from PBMCs on average 20,000-fold and routinely reached >80% purity. Expanded Vδ1 T cells showed a primarily naïve-like memory phenotype with limited exhaustion marker expression and displayed robust in vitro proliferation, cytokine production, and cytotoxic activity against HCC cell lines expressing low (PLC/PRF/5) and high (HepG2) GPC-3 levels. In a subcutaneous HepG2 mouse model in immunodeficient NSG mice, GPC-3.CAR/sIL-15 Vδ1 T cells primarily accumulated and proliferated in the tumor, and a single dose efficiently controlled tumor growth without evidence of xenogeneic GvHD. Importantly, compared with GPC-3.CAR Vδ1 T cells lacking sIL-15, GPC-3.CAR/sIL-15 Vδ1 T cells displayed greater proliferation and resulted in enhanced therapeutic activity. Conclusions Expanded Vδ1 T cells engineered with a GPC-3 CAR and sIL-15 represent a promising platform warranting further clinical evaluation as an off-the-shelf treatment of HCC and potentially other GPC-3-expressing solid tumors.
- 16 December 2021
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 9 (12) , e003441
Open AccessOff-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma
Background Glypican-3 (GPC-3) is an oncofetal protein that is highly expressed in various solid tumors, but rarely expressed in healthy adult tissues and represents a rational target of particular relevance in hepatocellular carcinoma (HCC). Autologous chimeric antigen receptor (CAR) αβ T cell therapies have established significant clinical benefit in hematologic malignancies, although efficacy in solid tumors has been limited due to several challenges including T cell homing, target antigen heterogeneity, and immunosuppressive tumor microenvironments. Gamma delta (γδ) T cells are highly cytolytic effectors that can recognize and kill tumor cells through major histocompatibility complex (MHC)-independent antigens upregulated under stress. The Vδ1 subset is preferentially localized in peripheral tissue and engineering with CARs to further enhance intrinsic antitumor activity represents an attractive approach to overcome challenges for conventional T cell therapies in solid tumors. Allogeneic Vδ1 CAR T cell therapy may also overcome other hurdles faced by allogeneic αβ T cell therapy, including graft-versus-host disease (GvHD). Methods We developed the first example of allogeneic CAR Vδ1 T cells that have been expanded from peripheral blood mononuclear cells (PBMCs) and genetically modified to express a 4-1BB/CD3z CAR against GPC-3. The CAR construct (GPC-3.CAR/secreted interleukin-15 (sIL)-15) additionally encodes a constitutively-secreted form of IL-15, which we hypothesized could sustain proliferation and antitumor activity of intratumoral Vδ1 T cells expressing GPC-3.CAR. Results GPC-3.CAR/sIL-15 Vδ1 T cells expanded from PBMCs on average 20,000-fold and routinely reached >80% purity. Expanded Vδ1 T cells showed a primarily naïve-like memory phenotype with limited exhaustion marker expression and displayed robust in vitro proliferation, cytokine production, and cytotoxic activity against HCC cell lines expressing low (PLC/PRF/5) and high (HepG2) GPC-3 levels. In a subcutaneous HepG2 mouse model in immunodeficient NSG mice, GPC-3.CAR/sIL-15 Vδ1 T cells primarily accumulated and proliferated in the tumor, and a single dose efficiently controlled tumor growth without evidence of xenogeneic GvHD. Importantly, compared with GPC-3.CAR Vδ1 T cells lacking sIL-15, GPC-3.CAR/sIL-15 Vδ1 T cells displayed greater proliferation and resulted in enhanced therapeutic activity. Conclusions Expanded Vδ1 T cells engineered with a GPC-3 CAR and sIL-15 represent a promising platform warranting further clinical evaluation as an off-the-shelf treatment of HCC and potentially other GPC-3-expressing solid tumors.
- Open Access
- 1 May 2018
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 200 (Supplement) , 181.15
Overcoming obesity-induced immunotherapeutic failure
Obesity is a leading public health concern that affects >37% of US adults and increases the risk of developing 13 types of cancer, including renal cancer. Renal cancer is treated by immunotherapy, but the impact of obesity on immunotherapy efficacy remains unclear. We addressed this issue by evaluating treatment efficacy in lean or diet-induced obese (DIO) mice with orthotopic renal tumors. Endogenous T cell priming with adenovirus-encoded TRAIL + CpG (AdTR/CpG) significantly reduced renal tumors in lean mice, but failed in ~80% of DIO mice. We then asked: 1) if failure were specific to this model and 2) if it could be reversed by reinvigoration of T cells with checkpoint blockade. Here, we report that obesity-induced impairment occurs across multiple immunotherapies and tumor types, and is independent of diet alone. Combining AdTR/CpG with checkpoint blockade (either anti-PD-1 or anti-CTLA-4) improved response rates in DIO mice with renal tumors to 44% and 67%, respectively. nanoString immunogenetic profiling of responder versus non-responder tumors revealed increases in T cell-related genes with concomitant decreases in myeloid/dendritic cell genes in responder mice (coined a ‘T cell-myeloid-inversion (TMI) signature’). These results were supported by flow cytometric data, which revealed increased intratumoral CD8+ T cell : Treg ratios and decreased myeloid-derived suppressor cells and tolerogenic dendritic cells in responders. Our results identify obesity as a confounder of immunotherapeutic efficacy that can be partially overcome by combining upstream T cell priming agents with checkpoint blockade. Further investigations will be aimed at targeting immunosuppressive populations to further boost therapeutic efficacy.
- 1 May 2018
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 200 (Supplement) , 181.15
Open AccessOvercoming obesity-induced immunotherapeutic failure
Obesity is a leading public health concern that affects >37% of US adults and increases the risk of developing 13 types of cancer, including renal cancer. Renal cancer is treated by immunotherapy, but the impact of obesity on immunotherapy efficacy remains unclear. We addressed this issue by evaluating treatment efficacy in lean or diet-induced obese (DIO) mice with orthotopic renal tumors. Endogenous T cell priming with adenovirus-encoded TRAIL + CpG (AdTR/CpG) significantly reduced renal tumors in lean mice, but failed in ~80% of DIO mice. We then asked: 1) if failure were specific to this model and 2) if it could be reversed by reinvigoration of T cells with checkpoint blockade. Here, we report that obesity-induced impairment occurs across multiple immunotherapies and tumor types, and is independent of diet alone. Combining AdTR/CpG with checkpoint blockade (either anti-PD-1 or anti-CTLA-4) improved response rates in DIO mice with renal tumors to 44% and 67%, respectively. nanoString immunogenetic profiling of responder versus non-responder tumors revealed increases in T cell-related genes with concomitant decreases in myeloid/dendritic cell genes in responder mice (coined a ‘T cell-myeloid-inversion (TMI) signature’). These results were supported by flow cytometric data, which revealed increased intratumoral CD8+ T cell : Treg ratios and decreased myeloid-derived suppressor cells and tolerogenic dendritic cells in responders. Our results identify obesity as a confounder of immunotherapeutic efficacy that can be partially overcome by combining upstream T cell priming agents with checkpoint blockade. Further investigations will be aimed at targeting immunosuppressive populations to further boost therapeutic efficacy.
- 18 October 2016
- Published by Springer Nature
- p. 143-168
The Future in Ovarian Cancer: Advances in Immunotherapies
- 18 October 2016
- Published by Springer Nature
- p. 143-168
The Future in Ovarian Cancer: Advances in Immunotherapies
- 19 September 2012
- Published by Springer Nature
- p. 235-251
Nanoparticle-Mediated Photothermal Therapy of Brain Tumors
- 19 September 2012
- Published by Springer Nature
- p. 235-251
Nanoparticle-Mediated Photothermal Therapy of Brain Tumors